Clinical efficacy of Sintilimab combined with vinorelbine and cisplatin chemotherapy in treatment of advanced non-small cell lung cancer
Objective To observe the effect of Sintilimab combined with vinorelbine+cisplatin chemotherapy on the prognosis of patients with advanced non-small cell lung cancer.Methods A prospective randomized controlled study was conducted,selecting patients with advanced non-small cell lung cancer admitted to the First People's Hospital of Pingdingshan from January 2020 to December 2021 as the study subjects.They were divided into two groups using a ran-dom number table method.The control group was treated with changchun vinorelbine+cisplatin chemotherapy,and the observation group was treated with Sintilimab plus changchun vinorelbine+cisplatin chemotherapy.The clinical effica-cy,prognosis,serum tumor marker levels[Carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cell Keratin 21-1 fragment(CYFRA21-1)],immune function(CD3+,CD4+,CD8+),and toxic side effects of drugs were compared.Results Compared with the control group,the observation group had higher objective response rate(ORR),disease control rate(DCR),and higher 1-year survival rate and average survival time(P＜0.05).After treatment,the serum tumor marker levels in the observation group were lower than those of the control group,and the improvement of immune function was better than that of the control group(P＜0.05).There was no significant differ-ence in the toxic side effects between the two groups(P＞0.05).Conclusion Sintilimab combined with vinorelbine+cisplatin chemotherapy regimen can effectively improve the clinical efficacy,prolong the survival period,improve im-mune function,and have better safety in patients with advanced non-small cell lung cancer.
NETL
NSTL
万方数据
